Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMpower010
  • Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

  • 04 Jun 2024 Results (clinical cutoff date: Jan 26, 2024) discussing Final disease-free survival (DFS) and second overall survival (OS) interim results after upto 5 years of follow up , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 10 Apr 2024 Results at data cutoff (Apr 18 2022, n=233) presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 24 Oct 2023 Results of exploratory analyses to identify predictive biomarkers for atezolizumab outcomes using IMpower010 RNA sequencing (RNAseq) data, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top